When Retrophin ousted its high-profile founder Martin Shkreli in October, the company didn't reveal why it had chosen to change management. Now those reasons are front and center as the biotech files suit against the former CEO, alleging a wide variety of misconduct.
The four-year-old biotech is accusing Shkreli of not only shirking his "duty of loyalty" to Retrophin, but using company funds...





